The global pharma analytical testing outsourcing market is expected to reach $14.6 billion by 2030, expanding at a CAGR of 8.4%, as per ReportLinker.

Bio-based drugs and biopharmaceuticals are likely to drive this growth as they require a high level of testing for validating efficacy and safety. Newer modalities, like cell and gene therapies (CGTs), bispecific and mRNAs, also present more complexities from a bioanalytical point of view which cannot be addressed in-house. Further, there is a growing need for high-end technology to measure the pharmacokinetics (PK) of very potent drugs or biomarkers that are too low to quantify. Some other factors driving the demand for bioanalytical outsourcing, include the need for speed in bioanalytical testing, increased regulatory scrutiny for bio-based drugs etc.

This article explores how CROs are adapting to the growing demand for bioanalytical services to accelerate client pipelines.

Syngene’s GLP-certified and US-FDA-inspected Bioanalytical laboratory offers full-service solutions for evaluating pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of biotherapeutics and vaccines. Our scientists have extensive experience working with monoclonal antibodies, recombinant proteins, enzymes, biomarkers, cytokines, vaccines, and hormones for both pre-clinical and clinical phases of drug development.

To learn more, contact our experts.